Clinical Trials Spotlight - Plaque Psoriasis
The Neurosciences & Sensory CTSU is currently supporting an exciting Phase 2, interventional study working to treat plaque psoriasis. Lead by PI Johann Gudjonsson, MD, PhD, Derm 677: Psoriasis and Riboflavin, is looking to determine the anti-inflammatory effect of high-dose riboflavin (also known as Vitamin B2) on chronic plaque psoriasis.
Chronic plaque psoriasis is a common skin disorder that affects more than 4 million people in the United States. There is currently no cure, and treatment is focused on controlling symptoms. Previous reports have suggested that riboflavin is clinically effective for the treatment of psoriasis, but this has not been conclusive. To test the effectiveness, participants in this study will receive 400mg of Riboflavin daily versus a placebo. The study will last 28 weeks with a crossover at the 12 week mark and a 4 week washout period.
"We are especially excited about this study," said study coordinator Aaron Rankin, "because lately many patients have great interest in treating their psoriasis with complimentary alternative medicine and vitamins."
Derm 677: Psoriasis and Riboflavin is currently seeking participants. To learn more about this study, click here.
Contact us at CTSOgroup@umich.edu.
The Molecular & Behavioral Neuroscience Institute, 205 Zina Pitcher Place, Ann Arbor, MI 48105
A list of CTSO-CTSU contacts are available in the Personnel Directory.